Burke & Herbert Financial Services Corp.·4

Jul 20, 3:50 PM ET

TISSUE ROBERT S 4

4 · Burke & Herbert Financial Services Corp. · Filed Jul 20, 2026

Research Summary

AI-generated summary of this filing

Updated

Burke & Herbert (BHRB) EVP Robert S. Tissue Exercises Options

What Happened

  • Robert S. Tissue, EVP of Financial Strategy at Burke & Herbert Financial Services (BHRB), exercised stock options on July 17, 2026 to acquire two tranches totaling 12,709 shares: 8,599 shares at $47.47 (cost $408,195) and 4,110 shares at $51.58 (cost $211,994), for an aggregate exercise cost of about $620,189.
  • To cover tax liability, 9,777 shares were withheld (reported as a disposition at $72.85 per share, value ~$712,254). The filing also shows the underlying option instruments were cancelled (derivative entries reported at $0) upon exercise.

Key Details

  • Transaction date: July 17, 2026.
  • Option exercises (code M): 8,599 shares @ $47.47 = $408,195; 4,110 shares @ $51.58 = $211,994 (total acquired 12,709 shares).
  • Tax/payment withholding (code F): 9,777 shares withheld/disposed @ $72.85 = $712,254.
  • Derivative cancellation: the exercised option interests were reported disposed at $0 (typical when options convert to common stock).
  • Filed: Form 4 filed July 20, 2026 (covers 7/17/2026 transactions); the report does not note any 10b5-1 plan or other special footnotes in the provided data.
  • Shares owned after the transaction: not provided in the data supplied.

Context

  • This was an option exercise (M) with a net-share or sell-to-cover style tax withholding (F): Tissue acquired shares by exercising options, and the company withheld 9,777 of those shares to satisfy tax obligations rather than Tissue paying cash.
  • Option exercises are a conversion of derivatives into stock (often neutral-to-bullish as the insider becomes a direct shareholder), while the withheld shares are routine tax-related dispositions and do not necessarily reflect a directional bet.

Insider Transaction Report

Form 4
Period: 2026-07-17
TISSUE ROBERT S
EVP, Financial Strategy
Transactions
  • Exercise/Conversion

    Common Stock

    2026-07-17$47.47/sh+8,599$408,19559,525 total
  • Exercise/Conversion

    Common Stock

    2026-07-17$51.58/sh+4,110$211,99463,635 total
  • Tax Payment

    Common Stock

    2026-07-17$72.85/sh9,777$712,25453,858 total
  • Exercise/Conversion

    Stock Settled Appreciation Rights

    2026-07-178,5990 total
    Exercise: $47.47From: 2019-02-07Exp: 2029-02-07Common Stock (8,599 underlying)
  • Exercise/Conversion

    Stock Settled Appreciation Rights

    2026-07-174,1100 total
    Exercise: $51.58From: 2017-02-09Exp: 2027-02-09Common Stock (4,110 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    373
Signature
/s/ Matthew Rucker, as Attorney-in-Fact for Robert S. Tissue|2026-07-20

Documents

1 file
  • 4
    wk-form4_1784577022.xmlPrimary

    FORM 4